A report from IQVIA shows China gaining ground in cancer drug R&D, and a growing industry focus on...
Author - simom
Following FDA’s full approval of Leqembi, here’s what else...
Leqembi’s U.S. approval is a milestone in Alzheimer’s research and medicine — and there are a...
Pharma’s strike-from-all-sides attack on the IRA could be...
New lawsuits challenging the Inflation Reduction Act’s price negotiation program hit the...
A BMS exec’s journey around the world in 90 days
As BMS grapples with upcoming patent cliffs, Emma Charles, the new SVP of intercontinental markets...
Astria Therapeutics’ edge in an ultra-rare disease
With positive early phase data, CEO Jill Milne is aiming to bring an improved preventative option...
Woman of the Week: Bayer’s Dr. Yesmean Wahdan
The VP of medical affairs and women’s health is focused on an audacious goal to meet the needs of...
This biotech CEO secured two billion-dollar Big Pharma deals...
With the industry focused on cancer and COVID-19, Marc de Garidel made deals centered on cardio.
Vaxxinity eyes global COVID-19 vaccine market with...
The biotech aims to complete rolling submissions with regulators in the U.K. and Australia in the...
Patients are using social media — clinical trial experts can...
Why an alliance of industry leaders is exploring the potential of social media as a treasure trove...
Weight loss drugs: the promise and pitfalls
GLP-1 agonists are dominating the anti-obesity scene — but hurdles remain to their uptake.